After performing a "deep dive" of both the ophthalmic and injectable product market, Piper Jaffray analyst David Amsellem says he continues to believe shares of Akorn are attractively valued. The company's abbreviated new drug application pipeline consists of over 80 pending filings, the analyst tells investors in a research note. He believes Akorn is well positioned to deliver "meaningful" long-term annual earnings growth even with the likely nearer-term erosion of injectable ephedrine due to increasing competition. Amsellem keeps an Overweight rating on the shares with a $35 price target.